Viral Therapy Efficacy Prediction via Replication Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including surgery, chemotherapy, and radiation, have limitations such as severe side effects and inability to treat all cancer types due to normal cell sensitivity, highlighting a need for more effective methods like viral therapy, which requires assessment of therapeutic virus efficacy for specific tumors.
Innovation Solution
A method is provided to predict the efficacy of viral therapy by introducing a therapeutic virus into tumor cells, assessing replication indicators, and using marker genes to determine if replication is delayed, thereby identifying suitable therapeutic viruses for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral therapy is used to treat cancer, then treatment effectiveness is improved, but the ability to predict efficacy for specific tumor types is insufficient
Solution Approach 1:
The patent performs preliminary assessment of viral replication capability in tumor cells before initiating full viral therapy. By introducing a test virus and measuring replication indicators (viral titer, protein expression) at early time points, the method predicts treatment efficacy in advance, allowing selection of appropriate viral candidates before committing to full therapy protocols.
Solution Approach 2:
The patent establishes a feedback mechanism where replication indicators measured during in vitro testing are used to predict in vivo treatment outcomes. The method correlates in vitro replication kinetics (viral titer changes, gene expression levels) with expected therapeutic efficacy, creating a feedback loop that guides clinical decision-making based on preliminary experimental data.
2Adaptability or versatility
If traditional cancer therapies (chemotherapy, radiation) are used, then treatment can be administered broadly, but severe side effects occur due to damage to normal cells
Solution Approach 1:
The patent employs viruses with selective replication properties that exhibit local quality - the virus replicates preferentially in tumor cells while sparing normal cells. This selectivity is achieved through viral engineering to target specific tumor cell characteristics, allowing the therapy to concentrate its effect locally at the tumor site without broadly affecting healthy tissue.
Solution Approach 2:
The patent utilizes parameter changes in viral behavior - specifically changes in replication rate, viral titer accumulation, and gene expression levels - to differentiate between tumor and normal cells. By monitoring these parameter changes during in vitro assessment, the method identifies viruses that exhibit appropriate parameter profiles for selective tumor targeting.
3Measurement precision
If viral replication assessment is performed thoroughly, then treatment selection accuracy is improved, but time and resource requirements increase
Solution Approach 1:
The patent applies partial action by measuring only the most critical replication indicators at strategically selected early time points rather than conducting exhaustive long-term replication studies. By focusing on key parameters (viral titer, protein expression) during the initial replication phase, the method achieves sufficient prediction accuracy without requiring complete characterization of the entire viral replication cycle.
Data Source
AI summary
Diagnostic methods and compositions associated with viral therapy are provided. In particular, methods, compositions, and kits to measure markers and therapeutic indicator predictive of viral efficacy in antitumor therapy are provided. Therapeutic viruses and combinations and kits for use in the practicing the methods also are provided.